<p>Fewer than 15% of patients eligible for device-aided therapy (DAT) in Parkinson’s disease are ever referred to a specialised centre. A central and underappreciated reason is terminological: the label “advanced Parkinson’s disease” carries a powerful psychological burden that causes patients who remain functionally active to reject the very therapy that could help them most. Patients who drove themselves to the appointment, who are still working and raising families, hear “advanced” and conclude that a threshold has been crossed toward dependency and decline. This mismatch is not a communication failure that better counselling can resolve; it is structural, embedded in guidelines, referral letters, consent forms, and patient-facing materials, and it operates before any clinical conversation begins. Moreover, the field currently speaks almost exclusively of ‘early’ and ‘advanced’ Parkinson’s disease, rendering invisible the prolonged intermediate phase where most patients actually live. We argue that the existing terminology is clinically imprecise, emotionally harmful, and functionally counterproductive. We propose replacing “advanced PD” with the term <i>fluctuation-dominant Parkinson’s disease</i> (FD-PD): a functional, mechanism-based descriptor for patients in whom motor and non-motor fluctuations, including dyskinesia, are the predominant feature of the disease experience, and whose primary unmet therapeutic need is inadequate dopaminergic coverage. FD-PD reframes the conversation from disease severity to therapeutic opportunity, decouples DAT eligibility from overall disease burden, names the unnamed intermediate disease phase, and will remain fit for purpose as less-invasive continuous dopaminergic therapies enter clinical practice. We call for a structured, international evaluation of whether FD-PD or a comparable functional descriptor merits formal adoption.</p>